Approval for the addition of safety and effectiveness clinical data and post-marketing surveillance data from the post approval studies performed as a condition of approval for the radiesse injectable implant. the device, as modified, will be marketed under thetrade name radiesse injectable implant and is indicated for subdermal implantation for the correction of moderate to severe facial wrinkles and folds, such as nasolabial folds and it is also intended for restoration and/or correction of the signs of facial fat loss (lipoatrophy) in people with human immunodeficiency virus.